In recent issues of *Critical Care*, Wu and colleagues \[[@B1]\] and Giamarellos-Bourboulis and colleagues \[[@B2]\] observed that cytokine responses in different concentrations of lipo polysaccharide (LPS) (1 and 10 pg/μL, respectively) stimulated peripheral blood mononuclear cells (PBMCs) of septic patients and healthy controls. Wu and colleagues found that interleukin-1beta (IL-1β) production of PBMCs from patients with sepsis was significantly higher than that from controls, whereas Giamarellos-Bourboulis and colleagues found the opposite result. In light of previous research, we would like to offer some remarks.

LPS can lead to the activation of nuclear factor-kappa-B (NF-κB) and the subsequent generation of pro-IL-1β \[[@B3]\], which is readily processe d into IL-1β by inflammasome-activated caspase-1 \[[@B4]\]. NF-κB also induces B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-X~L~), both of which could suppress the activation of caspase-1 by inhibiting NLRP1 (pyrin-containing nonobese diabetic-like receptor 1) and thus suppress the cleavage of pro-IL-1β \[[@B5]\]. When PBMCs were stimulated with low concentrations of LPS, the expression of pro-IL-1β could be predominant and functions of inflammasomes and caspase-1 were still reserved and thus IL-1β production was increased. When PBMCs were stimulated with high concentrations of LPS, the expression of Bcl-X~L~/Bcl-2 could greatly increase and lead to significant inhibition of caspase-1 and thus the production of IL-1β was decreased, although the expression of pro-IL-1β may not have been influenced significantly \[[@B2]\]. That may be the reason why the results of the two sets of authors were conflicting.

Since Bcl-2/Bcl-X~L~could be differently produced according to various concentrations of LPS, inhibiting Bcl-2/Bcl-X~L~with reagents like ABT-737 in order to make sure that inflammasome and caspase-1 are not suppressed *in vitro*would be necessary when trying to use LPS stimulation to assess the status of PBMCs from patients with sepsis.
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